Using Standards for EU IVDR Compliance

The IVDR is binding; standards provide methods and evidence

Regulation (EU) 2017/746 defines the legal requirements for IVDs. Harmonised standards can support conformity and, where correctly applied within the scope of a reference published in the OJEU, may provide a presumption of conformity for covered requirements. Other standards can still provide useful state-of-the-art methods.

Standards do not decide classification, establish intended purpose or substitute for performance evaluation. They help make the chosen methods repeatable, transparent and reviewable.

Define the IVD before selecting standards

An IVD standards strategy depends on whether the product is a reagent, calibrator, control material, specimen receptacle, instrument, software or system. It also depends on the analyte or measurand, specimen type, qualitative or quantitative output, user, setting, population, clinical condition and consequences of an incorrect result.

• Confirm that the product meets the IVDR definition and identify all accessories.
• Define intended purpose and performance claims precisely.
• Apply the IVDR classification rules and identify the conformity-assessment route.
• Establish Annex I GSPR applicability and Annex XIII performance-evaluation obligations.
• Identify common specifications and device-specific guidance.
• Define the complete system, including instruments, software, consumables, calibrators and controls.

Use MTL-102 — Intended Purpose, Users and Use Environments and MTL-301 — EU MDR and IVDR General Safety and Performance Requirements as the starting points.

Organise standards around the IVD performance model

IVDR performance evaluation connects scientific validity, analytical performance and clinical performance. Standards may define study designs, terminology, metrological concepts, stability approaches and statistical methods, but the manufacturer must justify that the evidence supports the stated intended purpose and claims.

MTL-119 — Clinical and Performance Evaluation and MTL-120 — Statistical Methods and Measurement Assurance explain these evidence disciplines in more detail.

Typical standards families for IVDs

The correct set is product-specific. The following families are common candidates; confirm the current edition, scope, OJEU status and any published restrictions before use.

Product-specific standards may be central—for example, ISO 15197 for blood-glucose monitoring systems—while broad standards alone may not address the claimed diagnostic performance.

Map standards to requirements, claims and studies

For each applicable GSPR and performance claim, identify the chosen standard clauses, method, acceptance criteria, study population or specimen set, configuration, evidence output and remaining gap. The map should distinguish process compliance from product-performance evidence.

Where a standard's population, specimen matrix, technology or statistical assumptions do not match the product, adapt or supplement the method and document the scientific rationale.

Example: a quantitative laboratory analyser

A laboratory analyser may combine assay reagents, calibrators, controls, specimen-handling processes, hardware, embedded firmware, application software and result reporting. Its standards set may include quality and risk standards; metrological traceability; precision, linearity, interference and detection-capability methods; instrument electrical safety and EMC; software lifecycle and usability engineering; labelling; and reagent-stability methods.

No single standard demonstrates IVDR conformity. A report showing good precision does not establish clinical performance; electrical-safety testing does not establish analytical accuracy; and software verification does not validate the medical meaning of a result. The performance-evaluation report must integrate the evidence for the intended purpose.

Use MTL-105 — Systems Engineering, Architecture and Interfaces to keep the complete analyser system and its evidence boundaries visible.

Build a reviewable IVDR evidence package

• Controlled standards-applicability register with edition and harmonisation status.
• GSPR matrix linking standards clauses, methods, reports and residual gaps.
• Performance-evaluation plan and report integrating scientific validity, analytical performance and clinical performance.
• Device-specific analytical study protocols, datasets, statistical analyses and conclusions.
• Risk traceability covering false results, invalid results, delays, workflow and interpretation.
• Software, instrument, usability, stability, labelling and manufacturing evidence.
• Post-market performance follow-up plan connected to claims and uncertainties.

The technical documentation should allow a reviewer to move from an IVDR requirement or claim to the applied method, controlled evidence and conclusion without reconstructing the logic from disconnected reports.

Maintain standards and performance evidence together

Monitor OJEU publications, standard revisions, common specifications, MDCG guidance and changes in scientific or clinical state of the art. Assess their effect on methods, acceptance criteria, calibration traceability, software, labelling, risk and marketed claims.

Lot performance, external quality information, complaints, invalid-result trends, literature and post-market performance follow-up may expose a need to revise the standards mapping or supplement an established method. Control these assessments through change management.

Common misconceptions

Practical checklist

• Define the complete IVD system, intended purpose and performance claims.
• Confirm classification, GSPRs, Annex XIII obligations and common specifications.
• Select standards whose scope matches the measurand, specimen, user, setting and technology.
• Check current OJEU references and document harmonisation status.
• Map every standard to requirements, claims, study methods and evidence.
• Justify deviations, adapted methods and unsupported areas.
• Integrate analytical and clinical conclusions in the performance-evaluation report.
• Connect risk controls to false, delayed, invalid and misinterpreted results.
• Maintain the mapping through changes and post-market performance follow-up.